<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33983653</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e12972</StartPage><MedlinePgn>e12972</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12972</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.12972</ELocationID><Abstract><AbstractText>The activation of the cannabinoid receptor type-2 (CB<sub>2</sub> ) afforded neuroprotection in amyotrophic lateral sclerosis (ALS) models. The objective of this study was to further investigate the relevance of the CB<sub>2</sub> receptor through investigating the consequences of its inactivation. TDP-43(A315T) transgenic mice were crossed with CB<sub>2</sub> receptor knock-out mice to generate double mutants. Temporal and qualitative aspects of the pathological phenotype of the double mutants were compared to TDP-43 transgenic mice expressing the CB<sub>2</sub> receptor. The double mutants exhibited significantly accelerated neurological decline, such that deteriorated rotarod performance was visible at 7&#xa0;weeks, whereas rotarod performance was normal up to 11&#xa0;weeks in transgenic mice with intact expression of the CB<sub>2</sub> receptor. A morphological analysis of spinal cords confirmed an earlier death (visible at 65&#xa0;days) of motor neurons labelled with Nissl staining and ChAT immunofluorescence in double mutants compared to TDP-43 transgenic mice expressing the CB<sub>2</sub> receptor. Evidence of glial reactivity, measured using GFAP and Iba-1 immunostaining, was seen in double mutants at 65&#xa0;days, but not in TDP-43 transgenic mice expressing the CB<sub>2</sub> receptor. However, at 90&#xa0;days, both genotypes exhibited similar changes for all these markers, although surviving motor neurons of transgenic mice presented some morphological abnormalities in absence of the CB<sub>2</sub> receptor that were not as evident in the presence of this receptor. This faster deterioration seen in double mutants led to premature mortality compared with TDP-43 transgenic mice expressing the CB<sub>2</sub> receptor. We also investigated the consequences of a pharmacological inactivation of the CB<sub>2</sub> receptor using the selective antagonist AM630 in TDP-43 transgenic mice, but results showed only subtle trends towards a greater deterioration. In summary, our results confirmed the potential of the CB<sub>2</sub> receptor agonists as a neuroprotective therapy in ALS and strongly support the need to progress towards an evaluation of this potential in patients.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cueto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Almer&#xed;a</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Toscano</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>Juli&#xe1;n</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillard</LastName><ForeName>Cecilia J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4490-0604</Identifier><AffiliationInfo><Affiliation>Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 DA041212</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043885">Receptor, Cannabinoid, CB2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009048" MajorTopicYN="N">Motor Skills</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043885" MajorTopicYN="N">Receptor, Cannabinoid, CB2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045442" MajorTopicYN="N">Rotarod Performance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CB2 receptors</Keyword><Keyword MajorTopicYN="N">TDP-43 (A315T) transgenic mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">reactive microglial cells</Keyword><Keyword MajorTopicYN="N">spinal cord</Keyword></KeywordList><CoiStatement>Cecilia Hillard is a member of the scientific advisory boards for Phytecs, Inc and Formulate Biosciences and has an equity share in Formulate Biosciences. The other authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33983653</ArticleId><ArticleId IdType="pmc">PMC8549023</ArticleId><ArticleId IdType="doi">10.1111/bpa.12972</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech 2017;10:537&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Fellner L, Haybaeck J, Wenning GK. Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down? J Neural Transm 2020;127:1097&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">32500222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:616&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall L, Anakor E, Connolly O, Vijayakumar UG, Duddy WJ, Duguez S. Molecular and cellular mechanisms affected in ALS. J Pers Med 2020;10:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7564998</ArticleId><ArticleId IdType="pubmed">32854276</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol 2016;138:225&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n&#x2010;S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 2011;72:257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur SJ, McKeown SR, Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene 2016;577:109&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Cruts M, Van Broeckhoven C. The genetics of C9orf72 expansions. Cold Spring Harb Perspect Med 2018;8:a026757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880162</ArticleId><ArticleId IdType="pubmed">28130313</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front Genet 2019;9:712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YC, Ng CS, Xiang P, Liu H, Zhang K, Mohamud Y, et al. Dysregulation of RNA&#x2010;binding proteins in amyotrophic lateral sclerosis. Front Mol Neurosci 2020;13:78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273501</ArticleId><ArticleId IdType="pubmed">32547363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji AL, Zhang X, Chen WW, Huang WJ. Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. J Med Genet 2017;54:145&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">28087719</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, Chia R. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 2020;14:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib AA, Mitsumoto H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 2011;16:537&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">21806316</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: A new drug approved for ALS. Cell 2017;171:725.</Citation><ArticleIdList><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 2008;14:2306&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">18781981</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter GT, Abood ME, Aggarwal SK, Weiss MD. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 2010;27:347&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20439484</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Bernardi G, Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 2010;224:92&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">20353778</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lago E, Moreno&#x2010;Martet M, Espejo&#x2010;Porras F, Fern&#xe1;ndez&#x2010;Ruiz J. Endocannabinoids and amyotrophic lateral sclerosis. In: Fattore L, editor. Cannabinoids in neurologic and mental disease. The Netherlands: Elsevier; 2015. p. 99&#x2013;124.</Citation></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Cueto C, Garc&#xed;a&#x2010;Toscano L, Santos&#x2010;Garc&#xed;a I, G&#xf3;mez&#x2010;Almer&#xed;a M, Gonzalo&#x2010;Consuegra C, Espejo&#x2010;Porras F, et al. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Br J Pharmacol 2021;178:1373&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">33486755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 1995;92:689&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42685</ArticleId><ArticleId IdType="pubmed">7846037</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman C, McAllister SD, Rizvi G, Patel SG, Moore DH, Abood ME. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:33&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15204022</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Hong S, Witting A, M&#xf6;ller T, Stella N, Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:182&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183560</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno&#x2010;Martet M, Espejo&#x2010;Porras F, Fern&#xe1;ndez&#x2010;Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex&#xae;&#x2010;like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther 2014;20:809&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6493201</ArticleId><ArticleId IdType="pubmed">24703394</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006;20:1003&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16571781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 2006;542:100&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16781706</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM&#x2010;1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007;101:87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819701</ArticleId><ArticleId IdType="pubmed">17241118</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. COX&#x2010;2, CB2 and P2X7&#x2010;immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006;6:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>Witting A, Weydt P, Hong S, Kliot M, M&#xf6;ller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem 2004;89:1555&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP&#x2010;43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009;106:18809&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao W, Jeong YH, Lin S, Ling J, Price DL, Chiang PM, et al. Rodent models of TDP&#x2010;43: recent advances. Brain Res 2012;1462:26&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613131</ArticleId><ArticleId IdType="pubmed">22608070</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP&#x2010;43 proteinopathy with drugs and drug&#x2010;like small molecules. Br J Pharmacol 2021;178:1298&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP&#x2010;43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2021;92:86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo&#x2010;Porras F, Piscitelli F, Verde R, Ramos JA, Di Marzo V, de Lago E, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP&#x2010;43 transgenic mice: relevance for a neuroprotective therapy in TDP&#x2010;43&#x2010;related disorders. J Neuroimmune Pharmacol 2015;10:233&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25819934</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo&#x2010;Porras F, Garc&#xed;a&#x2010;Toscano L, Rodr&#xed;guez&#x2010;Cueto C, Santos&#x2010;Garc&#xed;a I, de Lago E, Fernandez&#x2010;Ruiz J. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP&#x2010;43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Br J Pharmacol 2019;176:1585&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487601</ArticleId><ArticleId IdType="pubmed">29574689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Ruiz J, Romero J, Velasco G, Tol&#xf3;n RM, Ramos JA, Guzm&#xe1;n M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007;28:39&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17141334</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Ruiz J, Moro MA, Mart&#xed;nez&#x2010;Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 2015;12:793&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604192</ArticleId><ArticleId IdType="pubmed">26260390</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Trapero M, Espejo&#x2010;Porras F, Rodr&#xed;guez&#x2010;Cueto C, Coates JR, P&#xe9;rez&#x2010;D&#xed;az C, de Lago E, et al. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis Model Mech 2017;10:551&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451172</ArticleId><ArticleId IdType="pubmed">28069688</ArticleId></ArticleIdList></Reference><Reference><Citation>Espejo&#x2010;Porras F, Fern&#xe1;ndez&#x2010;Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post&#x2010;mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:377&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334787</ArticleId></ArticleIdList></Reference><Reference><Citation>Tol&#xf3;n RM, N&#xfa;&#xf1;ez E, Pazos MR, Benito C, Castillo AI, Mart&#xed;nez&#x2010;Orgado JA, et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta&#x2010;amyloid removal by human macrophages. Brain Res 2009;1283:148&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">19505450</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso E, Juv&#xe9;s S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer&#x2010;like phenotype in A&#x3b2;PP/PS1 mice. J Alzheimers Dis 2013;35:847&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">23515018</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez&#x2010;G&#xe1;lvez Y, Palomo&#x2010;Garo C, Fern&#xe1;ndez&#x2010;Ruiz J, Garc&#xed;a C. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 64:200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25863279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagredo O, Gonz&#xe1;lez S, Aroyo I, Pazos MR, Benito C, Lastres&#x2010;Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009;57:1154&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706932</ArticleId><ArticleId IdType="pubmed">19115380</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009;132:3152&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">19805493</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez A, Aparicio N, Pazos MR, Grande MT, Barreda&#x2010;Manso MA, Benito&#x2010;Cuesta I, et al. Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer's disease. J Neuroinflammation 2018;15:158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968596</ArticleId><ArticleId IdType="pubmed">29793509</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, Halang L, Woods I, Prehn JH. A high&#x2010;fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP&#x2010;43A315T mutant C57BL6/J mice. Dis Model Mech 2016;9:1029&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez FJ, Lafuente H, Rey&#x2010;Santano MC, Mielgo VE, Gastiasoro E, Rueda M, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic&#x2010;ischemic newborn piglets. Pediatr Res 2008;64:653&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18679164</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 2001;95:172&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11687290</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Weydt P, Howland DS, Kliot M, M&#xf6;ller T. Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. NeuroReport 2004;15:2513&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15538185</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Norden DM, Trojanowski PJ, Villanueva E, Navarro E, Godbout JP. Sequential activation of microglia and astrocyte cytokine expression precedes increased Iba&#x2010;1 or GFAP immunoreactivity following systemic immune challenge. 2016;Glia 64:300&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707977</ArticleId><ArticleId IdType="pubmed">26470014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Takeda T, Shibata N, Kobayashi M. Alterations in subcellular localization of TDP&#x2010;43 immunoreactivity in the anterior horns in sporadic amyotrophic lateral sclerosis. Neurosci Lett 2010;478:72&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20447446</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YF, Zhang YJ, Lin WL, Cao X, Stetler C, Dickson DW, et al. Expression of mutant TDP&#x2010;43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener 2011;6:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216869</ArticleId><ArticleId IdType="pubmed">22029574</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Ruiz&#x2010;Soto M, Villagr&#xe1; NT, Berciano J, Berciano MT, Lafarga M. Compensatory motor neuron response to chromatolysis in the murine hSOD1(G93A) model of amyotrophic lateral sclerosis. Front Cell Neurosci 2014;8:346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206191</ArticleId><ArticleId IdType="pubmed">25374511</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139(Suppl):27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori&#x2010;Tonou N, Yamashita H, Gutmann DH, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008;11:251&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Hyeon SJ, Im H, Ryu H, Kim Y, Ryu H. Astrocytes and microglia as non&#x2010;cell autonomous players in the pathogenesis of ALS. Exp Neurobiol 2016;25:233&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081469</ArticleId><ArticleId IdType="pubmed">27790057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>